- Company
- Keytruda can be prescribed for TNBC patients in Korea
- by Eo, Yun-Ho Dec 17, 2020 06:11am
- It is expected to be able to prescribe Keytruda, an immune anticancer drug, to patients with triple-negative breast cancer (TNBC) in Korea. According to related industries, MSD Korea recently submitted an application for additional indications for the combination of chemotherapy in the first line therapy of metastatic TNBC of PD-1 inhibito
- Company
- Pharmaceuticals' dilemma over the possibility of level 3
- by Kim, Jin-Gu Dec 17, 2020 06:11am
- While the government is considering level 3 of social distancing, the pharmaceutical industry is also taking countermeasures. Even if level 3 of social distancing are fully implemented, most of them maintain the flexible working system as they are now. However, internal discussions on the scope of essential manpower are in full swing in that
- Company
- The CEOs of eight multinational companies were replaced
- by Eo, Yun-Ho Dec 16, 2020 02:08pm
- Eight multinational pharmaceutical companies have appointed new CEOs during this year On the 14th, Dailypharm collected the current status of CEOs of major multinational companies in Korea, including 31 Korea Global Pharmaceutical Industry Associations (KRPIA) (currently). As a result, 8 pharmaceutical companies replaced or appointed new
- Company
- Prevymis by MSD is prescribed at Big 5 General Hospitals
- by Eo, Yun-Ho Dec 16, 2020 06:14am
- Prevymis, which is used to prevent cytomegalovirus infection in patients with allogeneic hematopoietic stem cell transplantation, can be prescribed at general hospitals. According to related industries, Prevymis (Letermovir), a prophylactic treatment for cytomegalo virus (CMV) infection in patients with allogeneic hematopoietic stem cell
- Company
- AbbVie expands autoimmune disease drug line-up fast
- by Eo, Yun-Ho Dec 15, 2020 06:04am
- AbbVie is quickly lining up next cash cows after Humira. Especially, the company’s speed of new drug reimbursement listing for the South Korean market has impressed the industry. The multinational company only took about six months and five months for an interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) and a Janus kinase (JAK) in
- Company
- Evenity, customized for patients with high risk of fracture
- by Dec 15, 2020 06:03am
- As Amgen's new osteoporosis treatment, Evenity (Romosozumab) was applied from this month, it could be used more by patients. In particular, Evenity, which has proven its strong efficacy in patients with high risk of fracture, may be useful. On the 10th, Amgen held an online meeting to commemorate the launch of Evenity insurance benefits, a
- Company
- The market for erectile dysfunction drugs is on the rise
- by Chon, Seung-Hyun Dec 15, 2020 06:03am
- The market for erectile dysfunction treatments is recovering. The market size contracted in the aftermath of COVID-19 in the first half, but it rebounded in the third quarter. Generic for Cialis have been largely succeeful. According to IQVIA, a drug research institute on the 10th, the market for erectile dysfunction treatments in the third
- Company
- Pfizer's Xeljanz XR (once a day), approved in Korea
- by Dec 14, 2020 05:58am
- Pfizer Korea (CEO Dong-wook Oh) &8203;&8203;announced on the 10th that it has received approval for Xeljanz XR 11 mg, a rheumatoid arthritis treatment, from the MFDS on the 7th. Xeljanz XR is a sustained-release tablet formulation of the existing Xeljanz 5mg (Tofacitinib). It can be used for the treatment of moderate to severe active rhe
- Company
- Bavencio, difficulty in expanding indication
- by Dec 11, 2020 06:16am
- The possibility of approval for a renal cell carcinoma indication for Bavencio(Avelumab), an immunotherapy developed by Merck and Pfizer, is very low. This is because the Central Pharmaceutical Affairs Review Committee of the MFDS has not recognized Bavencio's therapeutic effect. The Central Pharmaceutical Affairs Review Committee held a m
- Company
- AZ supplies 20 million doses of COVID-19 vaccines to Korea
- by Dec 10, 2020 06:09am
- The government announced a contract with AstraZeneca and other COVID-19 vaccine developers on the 8th, and AstraZeneca Korea said, "We are pleased to be able to supply (vaccine) for the public benefit." Korea AstraZeneca (CEO, Sang-pyo Kim) said on the day, "According to the contract with the KDCA, we will supply 20 million doses of AZD12
